After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...

Munich, Germany, January 14, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical ...

Eli Lilly said on Monday it would buy cancer therapy developer Scorpion Therapeutics for up to $2.5 billion in cash. Lilly ...

Leading biopharmaceutical company Pfizer has unveiled Cibinqo and Staquis, two innovative therapies designed to address eczema across its varying stages, now available in Malaysia. The announcement, ...

The FDA has granted fast track designation to emiltatug ledadotin for advanced or metastatic breast cancer treatment, as ...

Read on for expert advice on navigating all those menopausal mood shifts.Meet the experts: MargEva Morris Cole, MD, is an ...

The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif., Jan.

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Discover how low-dose lisinopril, an ACE inhibitor, could revolutionize male infertility treatments. This article explores ...

As of January 6, 2025, there were six evaluable patients in the Phase 2a arm evaluating IMM-1-104 with modified FOLFIRINOX in ...

A prediction for 2025 by Marci Chodroff, M.D., vice president of Medical Affairs at Prime Therapeutics and Managed Healthcare ...

Cogent Biosciences (COGT) highlighted the company’s key 2025 milestones ahead of its presentation at J.P. Morgan’s 43rd annual healthcare ...